At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 911 enrolled
Drug / intervention
AR101biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Longer-Term Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in a Prior AR101 Study
In Brief
A Phase 3 clinical trial evaluating AR101 for Peanut Allergy. Completed, enrolled 911 participants across 93 sites in 10 countries.
Detailed Summary
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Allergy
CountriesCanada, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartNov 2017
Primary CompletionApr 2023
TodayJul 2026
First PostedSep 25, 2017
Enrollment StartNov 2, 2017
Primary CompletionApr 27, 2023
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 8.8 years ago
Interventions
AR101biological
AR101